Inovio Pharmaceuticals (NASDAQ:INO) Releases Earnings Results, Misses Estimates By $0.02 EPS

Inovio Pharmaceuticals (NASDAQ:INOGet Rating) posted its earnings results on Tuesday. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02), MarketWatch Earnings reports. Inovio Pharmaceuticals had a negative net margin of 17,104.84% and a negative return on equity of 62.49%. The company had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.66 million. During the same quarter last year, the business posted ($0.27) EPS. Inovio Pharmaceuticals’s quarterly revenue was down 46.4% compared to the same quarter last year.

Shares of INO stock traded down $0.69 during mid-day trading on Wednesday, hitting $1.80. 483,707 shares of the stock traded hands, compared to its average volume of 4,562,018. Inovio Pharmaceuticals has a twelve month low of $2.34 and a twelve month high of $10.33. The firm has a market cap of $399.20 million, a price-to-earnings ratio of -1.17 and a beta of 0.80. The company’s 50-day simple moving average is $3.25 and its 200-day simple moving average is $4.63. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.82 and a current ratio of 6.82.

A number of brokerages have weighed in on INO. Oppenheimer lowered Inovio Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 5th. Royal Bank of Canada decreased their target price on Inovio Pharmaceuticals from $6.00 to $5.00 and set a “sector perform” rating for the company in a research report on Wednesday, March 2nd. Cantor Fitzgerald decreased their target price on Inovio Pharmaceuticals from $6.00 to $3.00 in a research report on Wednesday. Finally, Bank of America upgraded Inovio Pharmaceuticals from an “underperform” rating to a “neutral” rating and lifted their target price for the stock from $8.00 to $10.00 in a research report on Friday, January 21st. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating and six have given a hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.75.

Several hedge funds have recently modified their holdings of INO. Parametric Portfolio Associates LLC grew its holdings in shares of Inovio Pharmaceuticals by 3.4% in the 4th quarter. Parametric Portfolio Associates LLC now owns 136,064 shares of the biopharmaceutical company’s stock worth $679,000 after acquiring an additional 4,519 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Inovio Pharmaceuticals by 5.2% during the fourth quarter. Deutsche Bank AG now owns 135,512 shares of the biopharmaceutical company’s stock valued at $676,000 after buying an additional 6,756 shares in the last quarter. Wells Fargo & Company MN grew its holdings in shares of Inovio Pharmaceuticals by 5.8% during the second quarter. Wells Fargo & Company MN now owns 126,883 shares of the biopharmaceutical company’s stock valued at $1,175,000 after buying an additional 6,971 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Inovio Pharmaceuticals by 2.7% during the fourth quarter. California State Teachers Retirement System now owns 289,812 shares of the biopharmaceutical company’s stock valued at $1,446,000 after buying an additional 7,690 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in shares of Inovio Pharmaceuticals by 9.9% during the third quarter. Invesco Ltd. now owns 92,556 shares of the biopharmaceutical company’s stock valued at $662,000 after buying an additional 8,372 shares in the last quarter. Institutional investors own 43.28% of the company’s stock.

Inovio Pharmaceuticals Company Profile (Get Rating)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

Recommended Stories

Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.